Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA
IQWiG Laments Lack Of Comparative Data
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy, while Roche’s Evrysdi offers a hint of benefit in one patient group.
You may also be interested in...
Germany looks set to introduce new measures to curb pharmaceutical spending, including higher mandatory rebates for outpatient drugs and combination products. It will also lower the threshold at which orphan drugs must undergo a benefit assessment.
The G-BA, the body in charge of Germany’s pricing and reimbursement process, has confirmed that Novartis’s gene therapy Zolgensma (onasemnogene abeparvovec) offers no additional benefit over Biogen’s Spinraza (nusinersen) for treating spinal muscular atrophy.
Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.